NMG

Prkdc and Il2rg genes were both knocked-out in NOD mice. 

• Lacking mature T, B and NK cells
• Low immune rejection against human cells and tissues
• Good tumorigenicity so that a small number of cells can form tumors.
• Significant improvement in the survival of transplanted human cells and tissues
• Suitable for the transplantation of human hematopoietic stem cells and the preparation of humanized mouse models
• Suitable as the carrier mice for the transplantation of heterologous cells and tissues

Figure 1. Complete deletion of T, B and NK cells in the spleen of NMG mice.(A) The splenocytes of BALB/c, NOD-scid and NMG mice were collected to analyze their compositions of T, B and NK cells by FACS. (B) Statistical analysis of sorted cells.

Figure 2. Complete deletion of T, B and NK cells in the blood of NMG mice.(A) The peripheral blood samples of BALB/c, NOD-scid and NMG mice were collected to analyze their compositions of T, B and NK cells by FACS.(B) Statistical analysis of sorted cells.

Figure 3. Compositions of monocytes, macrophages, DCs in the spleen of NMG mice. (A) The splenocytes of BALB/c, NOD-scid and NMG mice were collected to analyze their compositions of monocytes, macrophages, DCs. (B) Statistical analysis of sorted cells.

Figure 4. Compositions of monocytes, macrophages, DCs in the blood of NMG mice. (A) The peripheral blood samples of BALB/c, NOD-scid and NMG mice were collected to analyze their compositions of monocytes, macrophages, DCs. (B) Statistical analysis of sorted cells.

Figure 5. Histological sections of various tissues from NMG mice. Furthermore, no significant abnormalities were observed in other tissues, including brain, retina, spinal cord, heart, liver, lung, kidney, small intestine, large intestine, stomach, salivary glands, pancreas, ovary, uterus, testis, epididymis, skeletal muscle, skin, and brown fat. 

Fig6.Serum antibody response in the serum of BALB/c, NOD-SCID, NMG and Blank. (n=5, 8-week-old, male)

Fig7. The establishment of tumor models using A549 or Raji cells is more effective in NMG mice.

A CDX model has been successfully established in NMG mice

Fig8. In vivo Efficacy Study of Anti-human CD47 Reference Antibody in the Treatment of Raji lymphoma CDX Tumor model in NMG mice.

Fig9. CAR-T in vivo efficacy study of A549 NSCLC model in NMG mice

Fig10. PBMC reconstitution model. Human PBMC cells were intravenous implanted into homozygote NMG mice. Percentage of human CD45+ cells (A),  body weight (B).

Fig11.  In vivo Efficacy Study of Hu-PBMC Reconstruction Model in NMG mice.

Fig12. Analysis of peripheral blood lymphocyte subpopulations of NMG mice after implantation of human CD34+ HSC at different times.

Fig13. Drug efficacy evaluation study performed in NMG mice reconstituted with hCD34+ cells. Humanized NMG mice reconstituted with human CD34+ cells were i.v. injected with MDA-MB-231 cells.

Peptide Self-Assembly Nanoparticles Loaded with Panobinostat to Activate Latent Human Immunodeficiency Virus
References：J Biomed Nanotechnol

SH3RF3 promotes breast cancer stem-like properties via JNK activation and PTX3 upregulation
References：NAT COMMUN

A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity
References：SCI TRANSL MED

Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model
References：Front. Immunol

Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
References：Cancers

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells
References：Frontiers in Immunology

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
References：nature communications

A Chimeric Conjugate of Antibody and Programmable DNA Nanoassembly Smartly Activates T cell for Precise Cancer Cell Targeting
References：A Journal of the Gesellschaft Deutscher Chemiker

Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer
References：SCIENCE ADVANCES

Exosome-derived circCCAR1 promotes CD8+T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma
References：Molecular Cancer

An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ
References：Molecular Therapy

Therapeutic strategies targeting uPAR potentiate anti–PD-1 efficacy in diffuse-type gastric cancer
References：SCIENCE ADVANCES

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
References：nature communications

Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma
References：International Journal of Molecular Sciences